149 related articles for article (PubMed ID: 20806177)
1. The differences in chromogranin A (CgA) concentrations measured in serum and in plasma by IRMA and ELISA methods.
Glinicki P; Kapuścińska R; Jeske W
Endokrynol Pol; 2010; 61(4):346-50. PubMed ID: 20806177
[TBL] [Abstract][Full Text] [Related]
2. Comparison of chromogranin A (CgA) levels in serum and plasma (EDTA2K) and the respective reference ranges in healthy males.
Glinicki P; Jeske W; Kapuścińska R; Zgliczyński W
Endokrynol Pol; 2015; 66(1):53-6. PubMed ID: 25754282
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies.
Molina R; Alvarez E; Aniel-Quiroga A; Borque M; Candás B; Leon A; Poyatos RM; Gelabert M
Tumour Biol; 2011 Feb; 32(1):13-22. PubMed ID: 20730520
[TBL] [Abstract][Full Text] [Related]
4. An Italian program of External Quality Control for chromogranin A (CgA) assay: performance evaluation of CgA determination.
Verderio P; Dittadi R; Marubini E; Pizzamiglio S; Gion M; De Apollonia L; Paradiso A;
Clin Chem Lab Med; 2007; 45(9):1244-50. PubMed ID: 17663633
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of CisBio ELISA for Chromogranin A Measurement.
Lim M; Erdman P; Cho S; Mathew A; Fleisher M; Thoren KL
J Appl Lab Med; 2019 Jul; 4(1):11-18. PubMed ID: 31639703
[TBL] [Abstract][Full Text] [Related]
6. Chromogranin A (CgA) in adrenal tumours.
Glinicki P; Jeske W; Bednarek-Papierska L; Kasperlik-Załuska A; Rosłonowska E; Gietka-Czernel M; Zgliczyński W
Endokrynol Pol; 2013; 64(5):358-62. PubMed ID: 24186592
[TBL] [Abstract][Full Text] [Related]
7. Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors.
Ferrari L; Seregni E; Lucignani G; Bajetta E; Martinetti A; Aliberti G; Pallotti F; Procopio G; Della Torre S; Luksch R; Bombardieri E
Int J Biol Markers; 2004; 19(4):295-304. PubMed ID: 15646836
[TBL] [Abstract][Full Text] [Related]
8. Comparison between two methods in the determination of circulating chromogranin A in neuroendocrine tumors (NETs): results of a prospective multicenter observational study.
Leon A; Torta M; Dittadi R; degli Uberti E; Ambrosio MR; Delle Fave G; De Braud F; Tomassetti P; Gion M; Dogliotti L
Int J Biol Markers; 2005; 20(3):156-68. PubMed ID: 16240843
[TBL] [Abstract][Full Text] [Related]
9. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study.
Zatelli MC; Torta M; Leon A; Ambrosio MR; Gion M; Tomassetti P; De Braud F; Delle Fave G; Dogliotti L; degli Uberti EC;
Endocr Relat Cancer; 2007 Jun; 14(2):473-82. PubMed ID: 17639060
[TBL] [Abstract][Full Text] [Related]
10. [Chromogranin A (CgA) - the influence of various factors in vivo and in vitro, and existing disorders on it's concentration in blood].
Glinicki P; Jeske W
Endokrynol Pol; 2011; 62 Suppl 1():25-8. PubMed ID: 22125107
[TBL] [Abstract][Full Text] [Related]
11. Comparison between two commercially available chromogranin A assays in detecting neuroendocrine differentiation in prostate cancer and benign prostate hyperplasia.
Zitella A; Berruti A; Destefanis P; Mengozzi G; Torta M; Ceruti C; Casetta G; Mosca A; Greco A; Rolle L; Aimo G; Aroasio E; Tizzani A; Dogliotti L; Fontana D;
Clin Chim Acta; 2007 Feb; 377(1-2):103-7. PubMed ID: 17034778
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of three commercially available ELISA kits for the determination of chromogranin A.
Eeckhout K; Van Cotthem K; Guerti K
J Immunoassay Immunochem; 2021 Mar; 42(2):95-105. PubMed ID: 33043835
[TBL] [Abstract][Full Text] [Related]
13. [Chromogranin A (CgA) - characteristic of the currently available laboratory methods and conditions which can influence the results].
Glinicki P; Jeske W
Endokrynol Pol; 2009; 60(5):415-9. PubMed ID: 19885814
[TBL] [Abstract][Full Text] [Related]
14. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas.
Qiao XW; Qiu L; Chen YJ; Meng CT; Sun Z; Bai CM; Zhao DC; Zhang TP; Zhao YP; Song YL; Wang YH; Chen J; Lu CM
BMC Endocr Disord; 2014 Aug; 14():64. PubMed ID: 25099181
[TBL] [Abstract][Full Text] [Related]
15. Chromogranin A immunoradiometric assay in diagnosis of pheochromocytoma: comparison with plasma metanephrines and 123I-MIBG scan.
Giovanella L; Squin N; Ghelfo A; Ceriani L
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):344-7. PubMed ID: 17043632
[TBL] [Abstract][Full Text] [Related]
16. Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours.
Monaghan PJ; Lamarca A; Valle JW; Hubner RA; Mansoor W; Trainer PJ; Darby D
Clin Endocrinol (Oxf); 2016 Mar; 84(3):348-52. PubMed ID: 26608723
[TBL] [Abstract][Full Text] [Related]
17. Automated two-site immunofluorescent assay for the measurement of serum chromogranin A.
Popovici T; Moreira B; Schlageter MH; Bories PN
Clin Biochem; 2014 Jan; 47(1-2):87-91. PubMed ID: 24201067
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the automated KRYPTOR chromogranin A assay with the DAKO ELISA.
Wolf M; Riedlinger I; Lehmann R; Häring HU; Schleicher E; Peter A
Clin Lab; 2014; 60(12):2103-6. PubMed ID: 25651748
[TBL] [Abstract][Full Text] [Related]
19. Preanalytical factors of importance for measurement of Chromogranin A.
Pedersen L; Nybo M
Clin Chim Acta; 2014 Sep; 436():41-4. PubMed ID: 24804936
[TBL] [Abstract][Full Text] [Related]
20. An Italian program of external quality control for chromogranin A (CgA) assay: state of the art of CgA measurement.
Italian Network for Quality Assessment of Tumor Biomarkers Group
Int J Biol Markers; 2005; 20(4):264-8. PubMed ID: 16398409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]